Techniques for selective activation of neurons in the brain, spinal cord parenchyma or peripheral nerve

• US 7,442,183 B2
• Filed: 11/09/2001
• Issued: 10/28/2008
• Est. Priority Date: 04/30/1999
• Status: Expired due to Fees

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Rise, Mark T., Baudino, Michael
• Primary Examiner(s): Slrmons; Kevin C.
• Assistant Examiner(s): WITCZAK, CATHERINE
• Application Number:
  US10/053,329
• Publication Number:
  US 20020062143A1
• Time in Patent Office: 2,545 Days
• Field of Search: 604/890.1, 604/891.1, 604/892.1, 604/93.01, 604 65- 67, 604/164.01, 604/164.08, 604/131, 60428801-28804, 128/DIG.12
• US Class Current: 604/93.01
• CPC Class Codes: A61M 2205/3523 using telemetric means
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: A61N 1/0529 Electrodes for brain stimulation
• CPC Class Codes: A61N 1/0534 Electrodes for deep brain stimulation
• CPC Class Codes: A61N 1/0551 Spinal or peripheral nerve electrodes
• CPC Class Codes: A61N 1/36071 Pain

Abstract

Techniques capable of selectively affecting and adjusting a volume of neural tissue in the brain, parenchyma of the spinal cord, or a peripheral nerve are disclosed. A lumen having at least one opening at its distal end that is capable of directing a lead outwardly along a predetermined trajectory is preferred. The lumen is capable of accepting a plurality of leads that can project outward in different directions from the distal end of the lumen. The leads have one or more electrodes at its ends and are thereby configured by the lumen in accordance with a predetermined two- or three-dimensional geometry. Anode/cathode relationships may be established between the electrodes by the operator to stimulate the neural tissue surrounding these electrodes. The operator may also adjust the stimulation to selectively stimulate the desired portion of the brain, spinal cord, peripheral nerve. Sensor feedback may be implemented to adjust the treatment therapy.

Claims

1. An implantable agent delivery system for providing treatment therapy to a volume of neural tissue comprising in combination:

a cannula having a central lumen distal end with a plurality of openings provided near the lumen distal end, each opening capable of directing a catheter outwardly along a distinct predetermined trajectory, at least one of the openings having a curved passageway defined by an inner curve and an outer curve, the inner curve and the outer curve having substantially the same shape so as to direct a catheter away from the central axis of the cannula along the predetermined trajectory, wherein, in operation, slicing caused by installation of the catheter may be substantially avoided;

a first catheter and a second catheter that are insertable within the cannula, wherein the first catheter protrudes through a first opening of the cannula and the second catheter protrudes through a second opening of the cannula, wherein each catheter is positioned to deliver a liquid agent, and wherein the liquid agent has a desired effect in providing the treatment therapy; and

a therapy delivery device that stores the liquid agent and couples to the first catheter and the second catheter to deliver the liquid agent, wherein the cannula, the first and second catheter and the therapy delivery device are each configured to be completely implantable under a skin of a patient.

2. The agent delivery system of claim 1, wherein the therapy delivery device comprises a replenishment port, and wherein additional liquid agent is inserted into the therapy delivery device through the replenishment port.

3. The agent delivery system of claim 2, wherein the additional liquid agent is injected with a hypodermic needle through the replenishment port.

4. The agent delivery system of claim 1, further comprising:

a first sensor that generates a first signal that is indicative of a condition to be treated; and

a processor that is coupled to the first sensor, that receives the first signal from the first sensor, and that causes the first catheter and the second catheter to deliver the liquid agent at a desired rate, wherein the first sensor and the processor are each configured to be completely implanted under the skin of the patient.

5. The agent delivery system of claim 4, wherein the therapy delivery device comprises a pump, and wherein the processor is coupled to the pump to provide the desired rate of infusing the liquid agent through said each catheter.

6. The agent delivery system of claim 4, wherein the processor is configured to perform:

(a) reading at least one parameter that is associated with the treatment therapy;

(b) obtaining a level of the first signal; and

(c) determining a desired rate of infusing the liquid agent through the first catheter and the second catheter according to the level of the first signal and the at least one parameter.

7. The agent delivery system of claim 6, wherein the processor is further configured to perform:

(d) adjusting the at least one parameter in response to the level of the first signal.

8. The agent delivery system of claim 7, wherein (d) comprises:

(1) if a timer has expired and if the at least one parameter has not changed during a corresponding time interval, reducing the at least one parameter.

9. The agent delivery system of claim 7, wherein (d) comprises:

(1) changing the at least one parameter in response to the level of the first signal; and

(2) resetting a timer to restart a corresponding time interval.

10. The agent delivery system of claim 6, wherein (c) comprises:

(1) if the agent delivery system is programmed to block neural activity, determining whether a target activity is excessive in accordance with the level of the first signal; and

(2) in response to (1), increasing at least one setting that is associated with the desired rate of infusing the liquid agent, wherein the at least one setting does not exceed a maximum value.

11. The agent delivery system of claim 10, wherein (c) further comprises:

(3) if the increasing in (2) would cause the at least one setting to exceeds the maximum value, providing an indicative output.

12. The agent delivery system of claim 6, wherein (c) comprises:

(1) if the agent delivery system is programmed to increase neural activity, determining whether a target activity is not sufficient in accordance with the level of the first signal; and

(2) in response to (1), increasing at least one setting that is associated with the desired rate of infusing the liquid agent, wherein the at least one setting does not exceed a maximum value.

13. The agent delivery system of claim 12, wherein (c) further comprises:

(3) if the increasing in (2) would cause the at least one setting to exceed the maximum value, providing an indicative output.

14. The agent delivery system of claim 4 further comprising a second sensor that generates a second signal that is indicative of the condition to be treated, and wherein the processor receives the second signal, and wherein the processor causes the first catheter and the second catheter to deliver the liquid agent in accordance with levels of the first signal and second signal.

15. The agent delivery system of claim 4, further comprising:

an interface that is connected to the processor, wherein the interface is configured to be completely implanted below the skin of the patient; and

a programmer that communicates to the processor through the interface to configure the processor in accordance with the therapy treatment.

16. The agent delivery system of claim 15, wherein the programmer communicates to the processor over a telemetry communications link.

17. The agent delivery system of claim 1, wherein the therapy delivery device is coupled to a first and a second catheter, wherein the delivery system is configured to deliver at least two drugs through the first and second catheters.

18. The agent delivery system of claim 1, wherein the treatment therapy is for a neurological disorder.

19. The agent delivery system of claim 1, wherein the liquid agent is selected from the group consisting of a medication and a drug.

20. An implantable drug delivery system that provides treatment therapy for a nervous system disorder to a volume of neural tissue comprising in combination:

a cannula having a lumen distal end with a plurality of openings provided near the lumen distal end, each opening capable of directing a catheter outwardly along a distinct predetermined trajectory, at least one of the openings having a curved passageway defined by an inner curve and an outer curve, the inner curve and the outer curve having substantially the same shape, so as to direct a catheter away from the central axis of the cannula along the predetermined trajectory, wherein, in operation, slicing caused by installation of the catheter may be substantially avoided;

a first catheter and a second catheter that are insertable within the cannula, wherein the first catheter protrudes through a first opening of the cannula and the second catheter protrudes through a second opening of the cannula, wherein each catheter is positioned to deliver a drug, and wherein the drug has a desired effect in providing the treatment therapy;

a pump that stores the drug and couples to the first catheter through a first catheter port and the second catheter through a second catheter port to deliver the drug at a desired rate;

a sensor that generates a signal that is indicative of a condition to be treated; and

a processor that is coupled to the sensor in order to receive the signal from the sensor and that instructs the pump to infuse the drug at the desired rate through the first catheter and the second catheter, wherein the cannula, the first and second catheter, the pump, the sensor and the processor are each configured to be completely implantable under a skin of a patient.

21. An implantable agent delivery system for providing treatment therapy to a volume of neural tissue comprising in combination:

a cannula having a lumen distal end with a plurality of openings provided near the lumen distal end, each opening capable of directing a catheter outwardly along a distinct predetermined trajectory, at least one of the openings having a curved passageway defined by an inner curve and an outer curve, the inner curve and the outer curve having substantially the same shape, so as to direct a catheter away from the central axis of the cannula along the predetermined trajectory, wherein, in operation, slicing caused by installation of the catheter may be substantially avoided;

a first catheter and a second catheter that are insertable within the cannula, wherein the first catheter protrudes through a first opening of the cannula and the second catheter protrudes through a second opening of the cannula, wherein each catheter is positioned to deliver a liquid agent; and

a therapy delivery device that stores the liquid agent and couples to the first catheter and the second catheter to deliver the liquid agent, wherein the cannula, the first and second catheter and the therapy delivery device are each configured to be completely implantable under a skin of a patient.

22. The agent delivery system of claim 21, wherein the first catheter is configured to deliver the liquid agent to a first position and the second catheter is configured to deliver the liquid agent to a second position, the agent delivery system further comprising:

a sensor that generates a signal, the sensor being located in a proximity of one of the positions; and

a processor that is coupled to the first sensor, that receives the signal from the sensor, and that causes the first catheter and the second catheter to deliver the liquid agent in accordance with the signal, wherein the sensor and the processor are each configured to be completely implanted under the skin of the patient.

23. The agent delivery system of claim 22, further comprising:

an interface that is connected to the processor, wherein the interface is configured to be completely implanted under the skin of the patient; and

an external programmer that communicates to the processor through the interface to configure the processor in accordance with the therapy treatment.

24. An agent delivery system of claim 21, wherein the therapy delivery has a port, and wherein additional liquid agent is inserted into the therapy delivery device through the port.

25. The agent delivery system of claim 21, wherein the treatment therapy is for a neurological disorder.